Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

When the disease appears later in life, it is referred to as acquired hemophilia. Appropriate treatment can control hemophilia in these instances. There is a possibility that the disease can ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Haemophilia, an uncommon genetic disorder ... while factor XI resides on chromosome 4. Acquired variety, however, occurs in ...